P/B
7,8
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
$1.9B
Market Cap • 9/23/2026
2019
(7 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
1931,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
4,6
EPS
—
Market Cap
Market Cap
1,9B
EV
1,6B
EV/Revenue
1585,9
EV/EBITDA
-3,3
EV/EBIT
-3,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-17,2%
Total Yield
-17,2%
Payout
0%
Retained Earnings
-957,6M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
21347,4%
Capex/Revenue
0,2%
Capex/D&A
6,5%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,1%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
0,7
Debt/Equity
0%
Current Ratio
9,9
Quick Ratio
9,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!